Carduso Capital invests in PIMS-E, a Spin-off company of the University of Groningen that aims to develop an epinephrine dry powder inhaler as alternative to Epipen™. More info
I. Sibum, P. Hagedoorn, H.W. Frijlink, F. Grasmeijer International Journal of Pharmaceutics, 2019, 11 (5) (DOI: 10.3390/pharmaceutics11050233)
M. Luinstra, A.W.F. Rutgers, T. van Laar, F. Grasmeijer, A. Begeman, V. Isufi, L. Steenhuis, P. Hagedoorn, A.H. de Boer, H.W. Frijlink Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease, Therapeutic Advances in Chronic Disease, 2019, 10 More info
M. Luinstra, V. Isufi, L. de Jong, A.W.F. Rutgers, P. Hagedoorn, J. Puttenstein, T. van Laar, H.W. Frijlink International Journal of Pharmaceutics, 2019, 567, p. 1-5 https://doi.org/10.1016/j.ijpharm.2019.118493
Ceintuurbaan Noord 152
9301 NZ Roden
The Netherlands
T: +31 (0)50 – 2053 325
F: +31 (0)50 – 2053 326
E: info@pureims.com